Literature DB >> 956350

Effects of dopamine infusion on pituitary hormone secretion in humans.

H Leblanc, G C Lachelin, S Abu-Fadil, S S Yen.   

Abstract

Dopamine, infused at a rate of 4 mug/kg/min for 3-4 h unaccompanied by any significant changes in cardiovascular dynamics, induced a prompt and sustained suppression of circulating prolactin (PRL) levels in normal men and women as well as in patients with hyperprolactinemia. At the discontinuation of the infusion, there was a marked rebound in PRL levels in normal subjects and a rapid return to basal levels in hyperprolactinemic patients. Dopamine infusion also induced a significant fall in LH levels in the normal subjects with a marked rebound in LH levels following the infusion. No significant changes in GH, TSH, and FSH levels were observed. These data indicate that in man a dopaminergic mechanism ixists in the regulation of PRL secretion and that dopamine also exerts an inhibitory effect of LH release.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 956350     DOI: 10.1210/jcem-43-3-668

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection.

Authors:  W Krause; T Mager; G Kühne; T Duka; B Voet
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

Review 3.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

4.  Inhibition of thyrotropin and prolactin secretion by dopamine in man.

Authors:  F Massara; F Camanni; V Vergano; L Belforte; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

5.  Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.

Authors:  S A Fine; L A Frohman
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

6.  Effect of the orally absorbed dopamine analogue N-methyldopamine diisobutyric ester on plasma prolactin levels.

Authors:  G Lombardi; A Tommaselli; C Fariello; A Quattrone; L Annunziato
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Effect of low-dose dopamine infusion on urinary prostaglandin E2 excretion in sick, preterm infants.

Authors:  I Seri; J Hajdu; J Kiszel; T Tulassay; A Aperia
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

8.  Dopamine decreases release of luteinizing hormone releasing hormone from superfused rat mediobasal hypothalamus.

Authors:  K Tasaka; A Miyake; T Sakumoto; T Aono
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

Review 9.  New concepts in the regulation of hypothalamic gonadotropin releasing hormone (GnRH) secretion.

Authors:  D D Rasmussen
Journal:  J Endocrinol Invest       Date:  1986-10       Impact factor: 4.256

10.  Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.

Authors:  G M Prelević; M I Würzburger; L A Perić
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.